Compare Stocks

C&J Energy Services, Inc. provides well construction, well completion, well support, and other complementary oilfield services and technologies to oil and gas exploration and production companies throughout the continental United States. It operates through Completion Services and Well Support Services segments. The Completion Services segment provides hydraulic fracturing; cased-hole solutions comprising cased-hole wireline, pumpdown, wireline logging, perforating, pressure pumping, well site make-up and pressure testing, and other complementary services; and well construction and intervention services, which include cementing, coiled tubing, rig services, fluids management, and other completion and well support services. This segment also engages in the engineering and production of various parts and components, such as perforating guns and addressable switches, which are used in the completion process. The Well Support Services segment offers rig services, such as providing workover and well servicing rigs that are primarily used for the routine repair and maintenance of oil and gas wells, re-drilling operations, and plugging and abandonment operations; fluids management services, including storage, transportation, and disposal services for fluids used in the drilling, completion, and workover of oil and gas wells; and other special well site services, such as fishing, contract labor, and tool rental services for the completion and workover of oil and gas wells. The company was founded in 1997 and is headquartered in Houston, Texas.

Falcon Oil & Gas Ltd., an oil and gas company, engages in the exploration, and development of unconventional oil and gas assets in Australia, South Africa, and Hungary. The company holds 22.5% interests in three exploration permits covering an area of approximately 1 million net acres in the Beetaloo Sub-basin, Northern Territory, Australia. It also holds a 100% interest in the technical cooperation permit covering an area of approximately 30,327.9 square kilometers in the southwest Karoo Basin, South Africa; and a 100% interest in the Makó production license covering an area of approximately 994.6 square kilometers in the Makó Trough located in south-eastern Hungary. The company was incorporated in 1980 and is headquartered in Dublin, Ireland.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's commercialized product is RUCONEST, a plasma-free rhC1INH protein replacement therapy for the treatment acute hereditary angioedema (HAE) attacks. It also engages in the development of leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome; OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE; and alpha-glucosidase therapy for the treatment of Pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. is headquartered in Leiden, the Netherlands.